Jeffrey Cummings

Jeffrey Irvine Cummings (born 1962) is an American lawyer from Illinois, who has served as a United States district judge of the United States District Court for the Northern District of Illinois since 2023. He previously served as a United States magistrate judge of the same court from 2019 to 2023. Provided by Wikipedia
Showing 1 - 20 results of 32 for search 'Jeffrey Cummings', query time: 0.05s Refine Results
  1. 1
    Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary

    Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary by Jeffrey Cummings

    Published 2023-07-01
    Get full text
    Article
  2. 2
    Commentary on: A call for better reporting of trials using surrogate primary endpoints

    Commentary on: A call for better reporting of trials using surrogate primary endpoints by Jeffrey Cummings

    Published 2022-01-01
    Get full text
    Article
  3. 3
    Disease modification and Neuroprotection in neurodegenerative disorders

    Disease modification and Neuroprotection in neurodegenerative disorders by Jeffrey Cummings

    Published 2017-09-01
    Get full text
    Article
  4. 4
    Correction to: New approaches to symptomatic treatments for Alzheimer’s disease

    Correction to: New approaches to symptomatic treatments for Alzheimer’s disease by Jeffrey Cummings

    Published 2021-04-01
    Get full text
    Article
  5. 5
    Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation

    Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation by Jeffrey Cummings, Jefferson Kinney

    Published 2022-07-01
    Get full text
    Article
  6. 6
    Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index

    Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index by Charles Bernick, Charles Bernick, Guogen Shan, Lauren Bennett, Jay Alberts, Jeffrey Cummings, Jeffrey Cummings

    Published 2021-07-01
    Get full text
    Article
  7. 7
    Who funds Alzheimer's disease drug development?

    Who funds Alzheimer's disease drug development? by Jeffrey Cummings, Justin Bauzon, Garam Lee

    Published 2021-01-01
    Get full text
    Article
  8. 8
    Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline

    Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline by Justin Bauzon, Garam Lee, Jeffrey Cummings

    Published 2023-08-01
    Get full text
    Article
  9. 9
    The “rights” of precision drug development for Alzheimer’s disease

    The “rights” of precision drug development for Alzheimer’s disease by Jeffrey Cummings, Howard H. Feldman, Philip Scheltens

    Published 2019-08-01
    Get full text
    Article
  10. 10
    The role of basket trials in drug development for neurodegenerative disorders

    The role of basket trials in drug development for neurodegenerative disorders by Jeffrey Cummings, Arturo Montes, Sana Kamboj, Jorge Fonseca Cacho

    Published 2022-05-01
    Get full text
    Article
  11. 11
    Sex Moderates Amyloid and Apolipoprotein ε4 Effects on Default Mode Network Connectivity at Rest

    Sex Moderates Amyloid and Apolipoprotein ε4 Effects on Default Mode Network Connectivity at Rest by Jessica Z. K. Caldwell, Xiaowei Zhuang, MacKenzie J. Leavitt, Sarah J. Banks, Jeffrey Cummings, Jeffrey Cummings, Dietmar Cordes, The Alzheimer's Disease Neuroimaging Initiative

    Published 2019-08-01
    Get full text
    Article
  12. 12
    Alzheimer's disease drug development pipeline: 2020

    Alzheimer's disease drug development pipeline: 2020 by Jeffrey Cummings, Garam Lee, Aaron Ritter, Marwan Sabbagh, Kate Zhong

    Published 2020-01-01
    Get full text
    Article
  13. 13
    Alzheimer's disease drug development pipeline: 2021

    Alzheimer's disease drug development pipeline: 2021 by Jeffrey Cummings, Garam Lee, Kate Zhong, Jorge Fonseca, Kazem Taghva

    Published 2021-01-01
    Get full text
    Article
  14. 14
    Alzheimer's disease drug development pipeline: 2023

    Alzheimer's disease drug development pipeline: 2023 by Jeffrey Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Feixiong Cheng

    Published 2023-04-01
    Get full text
    Article
  15. 15
    Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants

    Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants by Bruno Dubois, Christine A. F. von Arnim, Nerida Burnie, Sasha Bozeat, Jeffrey Cummings

    Published 2023-10-01
    Get full text
    Article
  16. 16
    Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

    Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemp... by Elizabeth Finger, Scott Berry, Jeffrey Cummings, Kristy Coleman, Robin Hsiung, Howard H. Feldman, Adam Boxer

    Published 2018-09-01
    Get full text
    Article
  17. 17
    An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home

    An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home by Gunnhild J. Hjetland, Gunnhild J. Hjetland, Gunnhild J. Hjetland, Inger Hilde Nordhus, Inger Hilde Nordhus, Ståle Pallesen, Ståle Pallesen, Jeffrey Cummings, Jeffrey Cummings, Rochelle E. Tractenberg, Rochelle E. Tractenberg, Eirunn Thun, Eirunn Thun, Eirin Kolberg, Elisabeth Flo

    Published 2020-03-01
    Get full text
    Article
  18. 18
    Alzheimer's disease drug development pipeline: 2022

    Alzheimer's disease drug development pipeline: 2022 by Jeffrey Cummings, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Fonseca, Kazem Taghva

    Published 2022-01-01
    Get full text
    Article
  19. 19
    The Alzheimer's Cell Atlas (TACA): A single‐cell molecular map for translational therapeutics accelerator in Alzheimer's disease

    The Alzheimer's Cell Atlas (TACA): A single‐cell molecular map for translational therapeutics accelerator in Alzheimer's disease by Yadi Zhou, Jielin Xu, Yuan Hou, Lynn Bekris, James B. Leverenz, Andrew A. Pieper, Jeffrey Cummings, Feixiong Cheng

    Published 2022-01-01
    Get full text
    Article
  20. 20
    Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

    Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease by Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri, Jeffrey Cummings

    Published 2022-04-01
    Get full text
    Article

Search Tools: